Poland· PL-100053170

Pimafucort

A hydrocortison und antibiotika product containing natamycinum + hydrocortisonum + neomycinum, registered in Poland by LEO Pharma A/S. The same ATC class is registered in 10 of our 19 countries.

ATC D07CA01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedPimafucortATCD07CA01REGISTER NO.PL-100053170PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Hydrocortison und antibiotika is registered in 10 of 19 countries.

Countries holding a registration under ATC D07CA01 (hydrocortison und antibiotika), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose

Hydrocortison und antibiotika · ATC D07CA01

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Natamycinum + Hydrocortisonum + Neomycinum
Manufacturer
LEO Pharma A/S
Country
Poland (PL)
ATC code
D07CA01
ATC class
Hydrocortison und Antibiotika
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909990210015

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Hydrocortison und antibiotika in 1 other country

What each register calls a product with the same active substance — salts and hydrates count as the same.

All hydrocortison und antibiotika products

Authorised across Europe · EMA

The same active substance is authorised in 1 EEA country. Names it is sold under:

  • Finland · Pimafucort

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ddbdad1d-a672-4534-bb28-f2560bc6ee91
GET /v1/drugs/ddbdad1d-a672-4534-bb28-f2560bc6ee91?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Maść",
  "source": "urpl",
  "strength": "(10 mg + 10 mg + 3500 I.U.)/g",
  "packaging": "Rp ¦ Skasowane ¦ 7978\n1 op. 5 g\n05909990210015 ¦ Rp ¦ 43922\n1 op. 15 g",
  "substance": "Natamycinum 10 mg + Hydrocortisonum 10 mg + Neomycinum 3500 IU",
  "common_name": "Natamycinum + Hydrocortisonum  + Neomycinum",
  "pl_product_id": "100053170",
  "pozwolenie_nr": "02100",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about hydrocortison und antibiotika.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.